About this project
The problem we solve: Over 285 million people in the world are visually impaired, of whom 39 million are blind and 246 million have moderate to severe visual impairment (WHO, 2014). It is predicted that without extra interventions, these numbers will rise to 75 million blind and 200 million visually impaired by the year 2020. The main causes of blindness are cataract (47.8%), glaucoma (12.3%), age related macular degeneration (8.7%), and diabetic retinopathy (4.8%), with the latter being on the rise. The elderly in particular are vulnerable to blinding diseases, such as glaucoma and cataracts.
A significant part of the problem is the inability to offer affordable and mobile test technology to wider populations who traditionally have limited access to healthcare.
About our solution: The Ceeable visual filed analyzer is a comprehensive, non-invasive, web-based screening and diagnosis system that can be easily used in clinical settings to detect early changes in visual function due to retinopathies such as glaucoma, age-related macular degeneration, and optic neuropathy.
The web-based screening system, employs an integrated and comprehensive visual field test system, called CVFA (Ceeable Visual Filed Analyzer). The technology is rapid (< 5 minutes per eye), easy (use of touchscreen), accurate (spatial resolution < 1 degree), non-invasive, and comprehensive. The technology automatically analyzes visual field data and objectively identifies and characterizes the occurring visual field defects. The Ceeable technology/test is flexible, light and can be performed anywhere in the world at low cost. This opens up the possibility of the product being used in urban and rural clinics by general practitioners and at optometry locations or at home.
Progress to date: The Ceeable test has been clinically validated on over 3000 patients to achieve the same results as the current standard of care. The test has been performed in traditional and non-traditional clinics from Mexico to Russia to the US.
About Our Team
Cynthia Matossian, MD Ophthalmology , Practicing Physician Location: Pennington , New Jersey Medical school: Penn State Hershey Medical Center Bio: Dr. Matossian is the sole owner, CEO and Medical Director of a large multi-specialty eyecare practice with over 60 employees. We offer a leading edge level of care, and have extensive experience in conducting clinical studies.
Practice: Matossian Eye Associates Title: Physician
About Team Members
CEO, BA Biography: Chris Adams has significant experience developing and commercializing new technologies in the medical device, pharmaceutical and software markets. He has been involved in the development of the leading corneal wound care device as both an inventor and CEO. His leadership experience includes forming scientific and business advisory boards, negotiating key corporate agreements and managing research collaborations. Wolfgang Fink
Chief Technology Officer, PHD Biography: Dr. Wolfgang Fink is an associate professor in Biomedical Engineering and Ophthalmology & Vision Science at the University of Arizona. He is a Visiting Associate in Physics at the California Institute of Technology. Dr. Fink is the inventor of the Ceeable visual field software platform. John Cerwin
Vice President Engineering, BS Biography: Mr. Cerwin has spent 30 years in the technology field as a software developer, systems architect, and entrepreneur. He is the sole inventor and assignee on four US patents, and participated in the development of several others. He has spent the last 16 years commercializing medical technologies, and has co-founded several companies offering software-based medical products. John has developed products for CVS and the DOD healthcare systems.
About Our Company
Ceeable, Inc. Location: Somerville, Massachusetts Website:http://ceeable.com Product stage: ready Sales: Less than $250,000 Employees: 3-5
How We Help Patients
Access to visual testing technology is important in preventing blindness. A mobile digital low cost visual testing solution that can be performed in the clinic or at home is an important medical tool in helping to detect and track eye disease. Ceeable delivers its vision test product over the internet directly to internet enabled devices and there is no software to download in order to run the test. The user/caregiver or patient logs into their account via a standard web browser. The company provides software updates, data storage, threshold alerts and progression monitoring. The patient data may be linked to the clinic or physician and programmed to receive regular updates or threshold alerts. In a telehealth application the patient may substitute the traditional office visit with the clinician by a phone call or video chat to discuss the most recent visual field exams performed on the Ceeable device.
How We Help Education
The Ceeable technology is a digital and mobile healthcare solution and technology that delivers its vision test products over the internet directly to internet enabled devices. Telehealth applications will be an important healthcare tool for physicians in this century. The blending of clinician experience and connected decision support systems will enable doctors to reach more patients outside of traditional clinic settings.
How We Help Physicians
For clinicians in ophthalmology or the general practitioner the Ceeable test delivers the same level of accuracy and precision as the standard of care instrumentation. The technology will allow providers to test more patients more frequently to detect monitor progression in eye disease. For example, diabetics who come in for routine office visits could take the Ceeable test to monitor changes in visual function. As a telehealth tool patients could monitor their condition at home and interact with the clinician virtually over the web or phone.
Mission: Ceeable' s mission is to provide its digital healthcare visual test solution across the globe to prevent blindness. Use of funds: Ceeable will use the grant funds to complete updates to the test user interface and migrate the software to a commercial server infrastructure. Intellectual Property Status: The Ceeable technology is protected by 14 US and international patents and applications (6 issued and 8 patent applications). The intellectual property covers the use of a touch enabled computer, alternating grid patterns, contrast levels and algorithms t Patent Link: http://autonomy.caltech.edu/patents/US9122956.pdf FDA Status: Based on a review by the company’s regulatory advisor we are preparing an FDA 510K application for clearance as a medical device to diagnose macular degeneration, glaucoma, optic neuropathy, and potentially several other conditions. The company will use the traditional Amsler grid and the Humphrey Visual Analyzer as a predicate devices, and anticipates a 6 month process. Personal Message: Ceeable' s mission is to provide its digital healthcare visual test solution to hospitals and clinics to developed and developing countries across the globe to prevent blindness.
05/15/2016paula alsobrooks- Nurse
Liked the project.
05/12/2016Bryan Song- Medical Student
Liked the project.
05/12/2016Bryan Song- Medical Student
Followed the project.
Cynthia Matossian, MD
Penn State Hershey Medical Center